Bifunctional antibodies targeting VEGFR2 and VEGFR3

By developing bifunctional antibodies that can specifically bind VEGFR2 and VEGFR3 to inhibit their dimerization, it solves the problem that existing treatment methods cannot effectively inhibit the spread of cancer cells, achieves effective inhibition of vascular and lymphatic regeneration, and reduces the side effect.

CN112272564BActive Publication Date: 2024-11-15NATIONAL HEALTH RESEARCH INSTITUTE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980020923.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-03-20
Filing Date
2019-03-20
Publication Date
2024-11-15
Estimated Expiration
2039-03-20

AI Technical Summary

Technical Problem

The existing anti-angiogenesis and lymphangiogenesis treatment methods cannot effectively inhibit the spread of cancer cells to lymph nodes and distant sites, resulting in poor efficacy in malignant tumor treatment, and the existing VEGFR inhibitors have greater side effects on normal organs.

Method used

A bifunctional antibody was developed that specifically binds VEGFR2 and VEGFR3, inhibiting their homogeneous and heterodimerization, thereby regulating the message transmission pathways between VEGFR2 and VEGFR3 and slowing down the rebirth of blood vessels and lymphatic vessels. The antibody contains specific heavy and light chain complementary determining region sequences that are able to bind to VEGFR2 and VEGFR3-like immunoglobulin domains, blocking dimerization without affecting ligand binding.

Benefits of technology

It effectively inhibits the dimerization of VEGFR2 and VEGFR3, slows down the rebirth of blood vessels and lymphatic vessels, has greater potential than existing VEGFR inhibitors, and has less side effects on normal organs, providing better therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112272564B_ABST
    Figure CN112272564B_ABST
Patent Text Reader

Abstract

The present invention relates to an isolated antibody comprising heavy chain complementary determining regions CDR1, CDR2, CDR3 and light chain complementary determining regions CDR1, CDR2, CDR3, wherein the heavy chain complementary determining regions are contained in a heavy chain variable region sequence having SEQ ID NO: 1 or 3, and the light chain complementary determining regions are contained in a light chain variable region sequence having SEQ ID NO: 2 or 4. The antibody can specifically bind to vascular endothelial growth factor receptor-2 (VEGFR2) and VEGFR3.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 62 / 645,437, filed on March 20, 2018, the entire contents of which are incorporated herein by reference. Background Art

[0003] In the process of tumor development, angiogenesis and lymphangiogenesis are necessary and highly correlated with whether the tumor is malignant. Their biological activity depends on the binding of vascular endothelial growth factor (VEGF) to its corresponding receptor (VEGFR), which can then dimerize the receptor and produce autophosphorylation reaction to activate downstream signals to promote cell proliferation, cell migration, vascular permeability and survival of new blood vessels. Olsson et al. (Olsson et al., Nat Rev Mol Cell Biol, 2006.7(5): p.359-71.) pointed out that VEGF-A and VEGF-C are the main VEGF ligands responsible for angiogenesis and lymphangiogenesis. Previous preclinical studies also revealed that if the effector is blocked from binding to VEGFR2 or VEGFR3, tumor growth can be effectively inhibited. However, referring to the relevant literature (Mukherji, SK, AJNRAm J Neuroradiol, 2010.31(2):p.235-6; Bagri, A., et al., Trends Mol Med, 2010.16(3):p.122-32), when the monoclonal antibody bevacizumab (Avastin) is used to block VEGF-A for tumor treatment, the efficacy of delaying progression and prolonging survival can only be achieved in some cancers. The main reason for the failure of clinical trials of this malignancy is that it is unable to slow down the growth of lymphatic vessels that can serve as a pathway for cancer cells to spread to lymph nodes and distant sites. Therefore, selective inhibitors of lymphangiogenesis can complement angiogenesis inhibitors to achieve the effect of inhibiting cancer. However, there is no relevant clinical application at present.

[0004] Currently, three strategies for blocking VEGFR signaling activation have been developed. In addition to the above-mentioned bevacizumab, which can be used as an anti-angiogenic ligand due to its cell growth inhibition mechanism, there is also aflibercept, which is a chimeric decoy receptor that can bind to VEGF and is currently undergoing advanced clinical trials (Ellis, LM, Semin Oncol, 2006. 33(5 Suppl 10): p. S1-7; and Holash, J., et al., Proc Natl Acad Sci USA, 2002. 99(17): p. 11393-8). The second type of inhibitors are small molecules, such as PTK787, Sutent, sorafinib, Zactima, Recentin, etc., which can inhibit the intracellular tyrosine kinase activity of VEGFR (Wedge, SR, et al., Cancer Res, 2002. 62(16): p.4645-55; Wedge, SR, et al., Cancer Res, 2005. 65(10): p.4389-400; Wood, JM, et al., Cancer Res, 2000. 60(8): p.2178-89; Mendel, DB, et al., Clin Cancer Res, 2003. 9(1): p.327-37; and Wilhelm, SM, et al., Cancer Res, 2004. 64(19): p.7099-109). Other therapies using large molecules, such as Ramucirumab (Cryamza) and CDP-791, can also be used to block the interaction between VEGF-A and VEGFR-2 (Krupitskaya, Y. and HAWakelee, Curr Opin Investig Drugs, 2009. 10 (6): p. 597-605; and Lu, D., et al., J Biol Chem, 2003. 278 (44): p. 43496-507). These agents are selective and well tolerated, and generally do not have too many side effects in inhibiting the expression of VEGF in normal organs.

[0005] VEGF receptor (VEGF receptor, VEGFR) is a more extensive family of receptor tyrosine kinases, mainly composed of VEGFR1, 2, 3, also known as Flt-1, KDR, Flt-4. The structure and functional domains of members of this family are highly similar, all of which contain 7 immunoglobin-like domains that can bind to ligands outside the cell, 1 transmembrane domain for cell-surface docking, and 1 dual tyrosine kinase domain that can cause receptor autophosphorylation (trans-autophosphorylation). For example, ligands such as VEGF-A and placental growth factor bind to VEGFR through immunoglobulin-like domains 2 and 3. Domain 2 is the main binding part, and domain 3 determines the specificity of binding (Christinger, HW, et al., J Biol Chem, 2004. 279 (11): p. 10382-8; Fuh, G., et al., J Biol Chem, 1998. 273 (18): p. 11197-204). In contrast, immunoglobulin-like domains 4-6 are involved in the dimerization of the receptor complex.

[0006] Theoretically, only when receptor dimerization and transphosphorylation occur can the downstream signal transduction pathway be continuously activated. Therefore, the angiogenesis or lymphangiogenesis activity caused by receptor participation can be inhibited by inhibiting the binding of ligands to receptors or blocking dimerization.

[0007] It is worth noting that inhibiting VEGFR-2 signaling by blocking dimerization can not only prevent the homodimerization of VEGFR2 and VEGFR3, but also interfere with the heterodimerization of VEGFR2 / VEGFR3. Therefore, this strategy of inhibiting tumor growth and tumor spread by inhibiting the signaling pathway involved in VEGR2 and VEGFR3 is a potential new mechanism. Summary of the invention

[0008] In one aspect, the present invention discloses an isolated antibody, which comprises heavy chain complementary determining regions CDR1, CDR2, CDR3 and light chain complementary determining regions CDR1, CDR2, CDR3, wherein the heavy chain complementary determining regions are derived from a heavy chain variable region sequence having a sequence of SEQ ID NO: 1 or 3, and the light chain complementary determining regions are derived from a light chain variable region sequence having a sequence of SEQ ID NO: 2 or 4, and the antibody can specifically bind to vascular endothelial growth factor receptor-2 (VEGFR2) and VEGFR3.

[0009] In some embodiments, the heavy chain CDR1, CDR2, and CDR3 are from SEQ ID NO:1, and the light chain CDR1, CDR2, and CDR3 are from SEQ ID NO:2, and the antibody may include a heavy chain variable region that is at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO:1; and a light chain variable region that is at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO:2.

[0010] In some embodiments, the heavy chain CDR1 has the sequence of SEQ ID NO: 5 or 8, the heavy chain CDR2 has the sequence of SEQ ID NO: 6 or 9, the heavy chain CDR3 has the sequence of SEQ ID NO: 7, and wherein the light chain CDR1, CDR2, and CDR3 have the sequences of SEQ ID NO: 10, 11, and 12, respectively.

[0011] In some embodiments of the present invention, the heavy chain CDR1, CDR2, and CDR3 are from SEQ ID NO: 3, and the light chain CDR1, CDR2, and CDR3 are from SEQ ID NO: 4. The antibody may include a heavy chain variable region sequence that is at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO: 3, and a light chain variable region sequence that is at least 80% (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO: 4.

[0012] In other embodiments, the heavy chain CDR1 has the sequence of SEQ ID NO: 13 or 16, the heavy chain CDR2 has the sequence of SEQ ID NO: 14 or 17, the heavy chain CDR3 has the sequence of SEQ ID NO: 15, and the light chain CDR1, CDR2, and CDR3 have the sequences of SEQ ID NO: 18, 19, and 20, respectively.

[0013] In some embodiments, the antibody comprises an Fc region, a Fab fragment, a Fab' fragment, a F(ab)'2 fragment, a single chain antibody, a scFV multimer, a monovalent antibody, a multispecific antibody or a chimeric antibody. In some embodiments, the antibody is a humanized antibody.

[0014] In another aspect, the present invention provides a pharmaceutical composition comprising the antibody disclosed in the present invention and a pharmaceutically acceptable carrier.

[0015] In another aspect, the present invention also discloses an antibody conjugate, which comprises the antibody disclosed in the present invention and other molecules (such as a small molecule drug, a cell targeting portion, a cytotoxic agent, a polypeptide, a nucleic acid molecule, a detectable marker or a polymer).

[0016] In one aspect, the present invention discloses a method for inhibiting homodimerization of VEGFR2 and / or VEGFR3 or heterodimerization of VEGFR2 and VEGFR3, the method comprising contacting a cell with the antibody disclosed in the present invention.

[0017] In one aspect, the present invention discloses a method for inhibiting VEGFR2 and / or VEGFR3 signaling pathways in a cell, comprising contacting the cell with an isolated antibody disclosed herein.

[0018] In another aspect, the present invention discloses a method for inhibiting angiogenesis and / or lymphangiogenesis in a subject in need thereof, comprising administering to the subject an effective amount of the antibody disclosed in the present invention.

[0019] In another aspect, the present invention discloses a method for treating a solid tumor in a subject in need thereof, comprising administering to the subject an effective amount of the antibody disclosed in the present invention. In some embodiments, the solid tumor is selected from bladder cancer, breast cancer, cervical cancer, colorectal cancer, rectal cancer, kidney cancer, liver cancer, skin cancer, mesothelioma, lung cancer, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, thyroid cancer; the method may further comprise administering to the subject another therapeutic agent.

[0020] In one aspect, the present invention discloses a method for detecting VEGFR2 and / or VEGFR3 or fragments thereof in a biological sample, comprising contacting the antibody with the sample; and determining the specific binding between the antibody and VEGFR2 and / or VEGFR3 or fragments thereof.

[0021] The drawings and the following description will elaborate on one or more embodiments of the present invention in detail. Other features, purposes, and advantages of the present invention will become more apparent through the following description, drawings, and scope of the patent application. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 The flow cytometry histogram group shows that monoclonal antibodies (mAbs) R2C7-1 and R2C9-11 are used to identify VEGFR2 and VEGFR3, respectively. Figure 1 A and 1B are primary human umbilical vein endothelial cells (HUVEC) and human lymphatic endothelial cells (HLEC), respectively. The experiments were conducted using primary cells of the third to sixth generations. Figure 1 C and Figure 1 D shows HEK293T cells overexpressing VEGFR2 and VEGFR3 (HEK293T / VEGFR2, HEK293T / VEGFR3). As shown in the figure, HEK293T cells can be stably transfected with human VEGFR2 or VEGFR3 genes, and antibodies targeting VEGFR2 or VEGFR3 (Abcam9530, R&D54703) are used on BD FACSJazz TM Cell sorter, immunostaining to select transfectants with high expression of VEGFR2 or VEGFR3, and then all primary cells or transfectants (1x10 5 Cells / reaction) were stained with R2C7-1 or R2C9-11 (10 μg / mL; arrows), while IgG2a isotype antibody (CTL) was used as a negative control group, and Ramucirumab (RAM) (10 μg / mL) was used as a positive control group for VEGFR2. In addition, cells stained only with the secondary antibody were considered as background values, and the number of positively stained cells was presented as a percentage of the total cells ( Figure 1 C, 1D; uppermost).

[0023] Figure 2 Ink dot plot and statistical graph for blocking receptor dimerization of VEGFR2 and VEGFR3, Figure 2 A is the result of co-immunoprecipitation. Erythroleukemia cells HEL92.1.7 (1x10 10 Cells / reaction) were treated with R2C7-1, R2C9-11 or Ramucirumab (20 μg / mL; RAM), or left untreated and treated with IgG2a isotype antibody (CTL) as negative control group. After treatment at 37°C for 24 hours, cells were trypsinized and centrifuged, fixed with 1% (w / v) paraformaldehyde and neutralized with glycine solution, and finally washed with PBS. 25 μg of antibody against VEGFR2 (Abcam9530) was added to the soluble fraction obtained by centrifugation and incubated at room temperature for 2 hours. Protein complexes bound to antibodies were immunoprecipitated (IP) by Protein A / G and immunoblotted (WB, left) for VEGFR3 of HEL92.1.7 cells, and fully soluble fractions were immunodetected with VEGFR3 and β-actin specific antibodies for normalization. Similarly, to precipitate VEGFR3 and dot-blot analysis of VEGFR2, HEK293T / VEGFR2 cells were transfected with plasmids carrying VEGFR3 (right). 24 hours after transfection, transfected cells were treated with R2C7-1, R2C9-11, or Ramucirumab (20 μg / mL), or left untreated and immunoprecipitated as described above. Figure 2 B is the result of proximity ligation assay (PLA), which detected the inhibitory effect of monoclonal antibodies R2C7-1 and R2C9-11 (10 μg / mL each) on VEGFR2 and / or VEGFR3 receptor dimerization. Human lymphatic endothelial cells (HLEC) were inoculated and cultured in serum-free medium containing R2C7-1, R2C9-11 or Ramucirumab (RAM) for 16 hours, followed by VEGF-A 165Each experiment was performed in triplicate, and the presence of fluorescent products was shown in the representative figure to demonstrate the close proximity (<40 nm) of homo- or hetero-dimerization of VEGFR2 and / or VEGFR3. Cell nuclei were stained with DAPI, and the fluorescent signals were visualized and quantified under a fluorescence microscope at 40x magnification using Image J analysis. Data results are expressed as mean ± SD values, which are expressed as the percentage of cells (CTL) without antibody treatment. In addition, cells treated with isotype control (IgG2a) were also used as another control group, while cells without any stimulation or cells treated with VEGF-A 165 or VEGF-C stimulation are indicated by blank, double cross or gray bars, respectively. Statistically significant differences between cells treated with antibodies and cells not treated with antibodies were calculated using t-test, * indicates P < 0.05.

[0024] Figure 3 The blocking effect of VEGFR2 antibody on human umbilical vein endothelial cells (HUVEC) and human lymphatic endothelial cells (HLEC) was shown. Figure 3 A, HUVEC cells were cultured in EGM-2 without any supplements or VEGF. The cells were starved for 8 h, then trypsinized, suspended in medium containing 10 μg / mL Ramucirumab, R2C7-1, R2C9-11, or isotype control antibody (IgG2a), and seeded on Matrigel-coated plates. They were then incubated with 2 μg / mL VEGF-A at 37°C. 165 The cells were stimulated for 10 h, and each of the above experiments was repeated three times; Figure 3 B, Similar to the above steps, HLECs were cultured in a starved state and pretreated with the above antibodies, and stimulated with 2 μg / mL VEGF-C for 4 hours at 37°C. The experimental results were captured by imaging, and the number of tube meshes, master junctions, tube length, and tubule area were quantified using Image J's Angiogenesis Analyzer. The data were expressed as percentages compared to the control group (IgG2A) (mean ± SD, triplicate), and *, **, and *** indicate P < 0.05, P < 0.01, and P < 0.001, respectively.

[0025] Figure 4The inhibitory effects of various VEGFR2 antibodies in a 3D angiogenesis model are shown. Endothelial cells (HUVEC and HLEC) were labeled with CFSE fluorescence and cultured in ultra-low 96-well plates at 37°C for 48 hours to form cell spheroids. Afterwards, the cell spheroids were transferred and attached to the well plates coated with Matrigel by centrifugation and cultured for 30 minutes. The attached cell spheroids were then cultured in a culture medium containing 10μg / mL R2C7-1, R2C9-11, Ramucirumab (RAM) or isotype control group antibody (CTL), and the shape of the cell spheroid core was observed and photographed using optical and fluorescence microscopy. The images captured after the 7th day of culture were the final images of HUVEV and HLEC. The fluorescence intensity was analyzed by NIS-AR software. The area and luminescence intensity of sprouting fibrins were obtained by subtracting the cell spheroid core from the total area and total luminescence intensity. The sprouting area (sprouting area, Figure 4 A) and its fluorescence intensity ( Figure 4 B) The data are presented as the percentage of the mean ± SD value, and the statistically significant differences between various VEGFR2 antibodies and CTL antibodies were determined by t-test, *** indicates < 0.001.

[0026] Figure 5 The results show that various VEGFR2 antibodies can inhibit angiogenesis and lymphangiogenesis in vivo. 6 ) / WI38(2x 10 5 ) cells, or HLEC (1x10 6 ) / WI38(2x 10 5) were suspended in 200 μL of ice-cold Matrigel, and then the cell mixture was subcutaneously inoculated into the left and right flanks of NOD-SCID mice using an ice-cold syringe with a 24-inch needle. The day after cell inoculation, mice were given intravenous injections twice a week at a dose of 10 mg / kg for 4 weeks. The polymerized matrix gel on the ventral side of the mouse was then removed, fixed with 10% formalin overnight, embedded in paraffin and cut into 5 μm thick tissue sections. Double staining was then used for immunohistochemical staining analysis. Human α-smooth muscle actin (α-SMA)-specific antibodies were used to identify HUVEC and HLEC with antibodies against WI38 and human CD31. NIS-AR software was then used to analyze and quantify the number of blood vessels or lymphatic vessels positive for AEC staining. The data are presented as percentages (mean ± SD) to compare the differences between three independent experiments and the control group. Statistically significant differences between each VEGFR2 antibody and CTL antibody were calculated by t-test. *, **, *** indicate P < 0.05, P < 0.01, and P < 0.001, respectively.

[0027] Figure 6 The difference in the ratio of large and small blood vessels in mice treated with VEGFR2 antibodies was shown. 6Cells / 500 μL Matrigel plug) were inoculated subcutaneously into the midline of the abdomen of NOD-SCID mice. On days 7, 14, 21, and 28 after inoculation, mice were given 10 mg / kg of IgG1 CTL, Ramucirumab (RAM), IgG2a CTL, R2C7-1, and R2C9-11 by intraperitoneal injection, and the mice were sacrificed on day 35. The tissue Matrigel was fixed with 10% formalin for 24 hours, embedded in paraffin, and cut into 5 μm thick tissue sections. Immunohistochemical staining with anti-human CD31 (hCD31) antibody was performed to identify the angiogenesis of HUVEC cells to analyze the effect of the antibody in inhibiting angiogenesis in vivo. The diameter of hCD31-positive blood vessels was measured under a microscope and divided into two groups: those with a diameter less than 50 μm and those with a diameter greater than 50 μm. The number of blood vessels in the two groups was then quantified. The left panel shows the ratio of the number of blood vessels in the group with a diameter greater than 50 μm to the total number of blood vessels after treatment with various antibodies; the right panel shows the ratio of the number of blood vessels in the group with a diameter less than 50 μm to the total number of blood vessels after treatment with various antibodies. The data from two independent experiments are presented as mean ± SD values. Statistically significant differences between each VEGFR2 antibody and its corresponding CTL antibody were calculated using t-test. * and ** indicate P < 0.05 and P < 0.01, respectively.

[0028] Figure 7 The antibody-dependent cytotoxicity (ADCC) of various VEGFR2 antibodies was shown. Figure 7 A is the expression level of VEGFR2 and VEGFR3. As indicated by the arrows, HEL92.1.7 cells were stained with antibodies specific for VEGFR2 (Abcam9530) or antibodies specific for VEGFR3 (R&D54703), respectively. The percentage of receptor expression was obtained by comparing with cells stained with isotype control group antibodies (CTL); Figure 7B shows its antibody-dependent cellular cytotoxicity, HEL92.1.7 cells (5x10 4 / each well, 25 μL) were inoculated into 96-well plates, and then 25 μL / well of the set concentration of R2C7-1, R2C9-11 or Ramucirumab (RAM) was added and incubated at 37°C for 15 minutes. In addition, peripheral blood mononuclear cells (PBMCs) of NOD-SCID mice were collected using a PBMC isolation reagent kit (MyBioSource) and were incubated at 4.0×10 6The cells / mL concentration was suspended in RPMI1640 medium containing 4% baby rabbit serum, and then 50 μL of PBMC effector was mixed with the target HEL92.1.7 cells in the well at a ratio of 4:1, and then PrestoBlue was added. TM Finally, the cell mixture was cultured at 37°C for 20 hours, and the cell viability was subsequently identified by measuring its fluorescence intensity (560nm / 590nm).

[0029] Figure 8 The ability of various VEGFR2 antibodies to inhibit tumor growth was demonstrated. Using a flow cytometer (BeckmanCoulter CytoFLEX S), HEL92.1.7 cells with high expression of VEGFR3 (i.e. Figure 8 A, which accounts for more than 95% of the whole population), and HEL92.1.7 cells with low expression of VEGFR3 (i.e. Figure 8 B, which accounts for less than 5% of the whole population) and cell expansion. High-expression and low-expression cells were injected subcutaneously into the right and left sides of the back of the same mouse (1x10 6 / mouse). On the 7th day after tumor inoculation, 5 mice were grouped together and each group was given 5 mg / kg of specific antibody treatment (RAM, R2C7-1, R2C9-11) twice a week for 25 days. The isotype control group IgG2a (CTL) was also treated with the same steps. The tumor size of each mouse was measured twice a week. The average tumor size was measured after the mice were sacrificed. Figure 8 A and Figure 8 (B), the differences between the groups treated with different antibodies and the control group were analyzed by t-test, *, ** indicate P < 0.05, P < 0.01, respectively.

[0030] Fig. 9 The ability of different VEGFR2 monoclonal antibodies to inhibit tumor growth was shown. HEL92.3.1 cells were inoculated subcutaneously into NOD-SCID mice (1x10 6 / mouse), as shown in the figure, 10 mice per group, a total of 6 groups, 7 days after inoculation, were given R2C7-1, R2C9-11, RAM (each mouse dose was 5 mg / kg), or RAM (5 mg / kg) plus one of R2C7-1 and R2C9-11 (5 mg / kg) by intravenous injection twice a week for a total of 35 days. The mice that were only given a single VEGFR2 antibody were given the same dose of IgG2a isotype control group antibody (CTL) so that the total amount of antibody in each mouse was 10 mg / kg. Use the modified ellipse formula: [Tumor volume = 1 / 2 (length × width 2 )](Tomayko MM, Reynolds CP.,1989) The tumor volume of each mouse was calculated. The data are expressed as mean ± SD values ​​to represent the mean tumor size (as shown in the inset). The statistically significant difference between VEGFR2 antibody and CTL antibody was calculated by t-test. *, **, *** indicate P < 0.05, P < 0.01, P < 0.001, respectively.

[0031] Fig.10 The binding epitopes of R2C7-1 and R2C9-11 antibodies on VEGFR2 were characterized. HEK293T cells expressing VEGFR2 (293T / VEGFR2) were cultured at 1x10 6 Cells / 100 μL were inoculated in a 96-well plate and cultured overnight at 37°C. In addition, the optimal concentration of R2C7-1 and R2C9-11 antibodies binding to cells was determined using a standard ELISA procedure, and the optimal concentrations of R2C7-1 and R2C9-11 monoclonal antibodies (200 μg / mL and 50 μg / mL, respectively) were combined with the single immunoglobulin-like domain (R2-IgDs) of the VEGFR2 antigen at the set dose. 293T / VEGFR2 cells fixed with glutaraldehyde and washed were co-cultured with the bound antibodies at 37°C for 30 minutes, and then the bound antibodies were detected using a goat-anti-mouse IgG antibody with HRP, followed by the addition of ABTS for color development, and the SpectraMax microplate analyzer was used at OD 405 The absorbance was measured at the bottom. The data are expressed as mean ± SD values ​​representing the percentage of triplicate experiments of the isotype control group (CTL). The potential epitope positions of R2C7-1 and R2C9-11 on the VEGFR2 antigen (upper and lower figures, respectively) are indicated by the black lines across IgD6 and IgD7 in the figures.

[0032] Fig.11 The binding epitopes of R2C7-1 and R2C9-11 antibodies were determined on the VEGFR3 antigen. Fig.11 A is a cell-type competitive ELISA result diagram. HEK293T cells expressing VEGFR3 (293T / VEGFR3) were first coated on a 96-well plate. As described above, the optimal concentrations of R2C7-1 and R2C9-11 monoclonal antibodies were measured (data not shown). The optimal concentrations of R2C7-1 and R2C9-11 monoclonal antibodies were bound to the single immunoglobulin-like domain (R3-IgDs) of the VEGFR3 antigen at the set dose. The bound antibodies were detected using a secondary antibody with HRP, and then ABTS was added for color development, and the SpectraMax microplate analyzer was used to analyze the OD 405 The absorbance was measured below, and the data are expressed as mean ± SD values ​​compared to the percentage of triplicate experiments of the isotype control group (CTL). The potential epitope locations of R2C7-1 and R2C9-11 on the VEGFR3 antigen (upper and lower figures, respectively) are indicated by the black line across IgD6 in the figure. Fig.11 B is the result of native gel electrophoresis. Constructs of the entire extracellular domain (R3-IgD1-7), domain 3-4 (R3-IgD3-4), and domain 6-7 (R3-IgD6-7) were first prepared and expressed in E. coli. They were then purified using an anti-Myc affinity purification system. Anti-Myc antibodies were used as probes to perform standard Western blotting to detect the purity and molecular weight of each recombinant protein (left figure). In addition, native gel electrophoresis was performed to detect the binding between R2C7-1, R2C9-11 and truncated VEGFR3 antigens to confirm the epitopes of the R2C7-1 and R2C9-11 monoclonal antibodies (middle and right figures, respectively). DETAILED DESCRIPTION

[0033] The present invention discloses a bifunctional antibody that can specifically target vascular endothelial growth factor receptor-2 (VEGFR2) and vascular endothelial growth factor receptor-3 (VEGFR3). The antibody can inhibit the homodimerization of VEGFR2 and VEGFR3 or the heterodimerization between them, but does not affect the binding with their ligands. Therefore, the antibody can regulate the signal transduction pathway of VEGFR2 and VEGFR3 and inhibit angiogenesis and lymphangiogenesis.

[0034] In some embodiments, the heavy chain complementary determining regions (CDRs) CDR1, CDR2, and CDR3 of the antibody are derived from a heavy chain variable region sequence having SEQ ID NO: 1 or 3, and the light chain complementary determining regions CDR1, CDR2, and CDR3 are derived from a heavy chain variable region sequence having SEQ ID NO: 2 or 4.

[0035] In some embodiments, the heavy chain CDR1 may have a sequence of SEQ ID NO: 5, 8, 13 or 16; the heavy chain CDR2 may have a sequence of SEQ ID NO: 6, 9, 14 or 17; the heavy chain CDR3 may have a sequence of SEQ ID NO: 7 or 15; the light chain CDR1 may have a sequence of SEQ ID NO: 10 or 18; the light chain CDR2 may have a sequence of SEQ ID NO: 11 or 19; and the light chain CDR3 may have a sequence of SEQ ID NO: 12 or 20.

[0036] In some embodiments, the antibody binds to an epitope located within the IgD6 and IgD7 domains of VEGFR2 and an epitope within the IgD6 domain of VEGFR3, and the epitope may be structural.

[0037] The term "antibody" described herein includes various antibody structures with antigen-binding ability, including monoclonal antibodies, polyclonal antibodies, full-length antibodies or fragments thereof, antibodies containing Fc regions, Fab fragments, Fab' fragments, F(ab')2 fragments, single-chain antibodies, scFV multimers, monovalent antibodies, multivalent antibodies, humanized antibodies, chimeric antibodies, but are not limited to the above types.

[0038] The antibody may also be conjugated to another molecule, such as a small molecule drug, another protein or peptide, a detectable label, a polymer, or a carbohydrate.

[0039] Since the present invention discloses the antibody sequences and their CDRs, a person skilled in the art can prepare anti-VEGFR2 / anti-VEGFR3 antibodies in various forms by using the methods of the present invention or techniques known in the art, such as recombinant methods.

[0040] In addition, the present invention also discloses an isolated nucleic acid molecule (e.g., an expression vector) encoding the antibody or its components. For example, the isolated nucleic acid molecule can be a nucleic acid molecule that can encode any sequence in SEQ ID NO: 1-20. The present invention also discloses a host cell containing the nucleic acid molecule. The nucleic acid molecule and the host cell can be used to produce antibodies.

[0041] The antibodies disclosed in the present invention can be used to block homodimerization of VEGFR2 and / or VEGFR3 or heterodimerization of VEGFR2 and VEGFR3, block signal transduction of VEGFR2 and / or VEGFR3, or inhibit angiogenesis and / or lymphangiogenesis. The antibodies can also be used in immunoassays (such as ELISA) to detect whether a sample contains VEGFR2 and / or VEGFR3 or fragments thereof. The antibodies can bind to and detect VEGFR2 or VEGFR3 fragments containing the IgD6-IgD7 domain.

[0042] In addition, the antibody can be used to treat solid tumors, such as bladder cancer, breast cancer, cervical cancer, colorectal cancer, rectal cancer, kidney cancer, liver cancer, skin cancer, mesothelioma, lung cancer, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, and thyroid cancer.

[0043] The "sample" herein can be any biological sample, such as a body fluid sample, a blood sample, a cell sample, a urine sample, a saliva sample or a tissue sample.

[0044] The antibodies disclosed in the present invention can be prepared into pharmaceutical compositions suitable for various routes of administration, such as intravenous, intra-articular, conjunctival, intracranial, intraperitoneal, intrathoracic, intramuscular, intraspinal or subcutaneous administration. The pharmaceutical composition can be an aqueous solution or a lyophilized preparation, and can contain a pharmaceutically acceptable carrier, such as a buffer, an excipient, a stabilizer or a preservative; the pharmaceutical composition can contain other active ingredients that can act together with the antibody, such as another therapeutic agent or an adjuvant.

[0045] The following specific embodiments are only used to illustrate the present invention and are not intended to limit the rest of the present invention in any way. Based on the contents disclosed in this case, a person with ordinary knowledge in the art can fully utilize the present invention without further detailed description. The public documents cited herein are all fully incorporated into the present invention as references.

[0046] It is assumed that therapeutic antibodies that can target the immunoglobulin-like domains 4-7 of VEGFR-2 can achieve therapeutic effects without being affected by ligands, and can be regarded as a discriminative mode of activation of the signaling of the targeted VEGFR-2. The following describes the preparation of therapeutic antibodies R2C7-1 and R2C9-11 that can target VEGFR-2, as well as their inhibitory effects in in vitro and in vivo angiogenesis and lymphangiogenesis model systems.

[0047] Preparation of bifunctional antibodies that block VEGF-R2 / -R3 dimerization

[0048] Receptor dimerization of VEGFR2 and / or VEGFR3 is a necessary condition for activating its downstream signal transduction pathway to carry out the biological activity function of its specific ligand. It has been pointed out in the literature that VEGF-A and VEGF-C can lead to homodimerization of VEGFR2 or heterodimerization with VEGFR3. Therefore, if the dimerization region on VEGFR2 is targeted, it may be possible to effectively block the activation of signal transduction mediated by VEGFR2 and / or VEGFR3 receptors, thereby inhibiting the disease mechanisms induced by VEGFR-A and VEGFR-C, such as angiogenesis, lymphangiogenesis, tumor metastasis, diabetic retinopathy and vasculitis in rheumatoid arthritis.

[0049] In order to test this hypothesis, a plasmid with the sequence of the dimerization region of VEGFR2, that is, its immunoglobulin-like domains 4 to 7 (IgD4-7) sequence, was constructed and expressed in an E. coli expression system. The recombinant protein was then purified using a His-tag affinity column and inoculated into mice. The spleen cells of the mice were then fused with Sp2 / 0-Ag14 myeloma cells to produce a hybridoma library. Initially, two hybridoma cell lines (R2C7 and R2C9) were selected for subsequent experiments because they had high affinity for HUVEC cells and had a significant inhibitory effect on tube formation. In order to ensure that the two hybridomas were each a single population, the two hybridomas were selected by limiting dilution method, and the resulting hybridoma cell lines were named R2C7-1 and R2C9-11. The functions of the two antibodies were also tested, including detailed characterization of their physical properties.

[0050] Dual targeting of VEGFR2 and VEGFR3

[0051] In order to test the binding specificity of the newly developed monoclonal antibodies R2C7-1 and R2C9-11, HUVEC cells and HEK293T cells expressing VEGFR2 (HEK293T / VEGFR) were used as experimental models. The results showed that both antibodies had comparable affinity for VEGFR2 expressed by HUVEC cells ( Figure 1A, 1C). To further determine the binding affinity of R2C7-1 and R2C9-11, HEK293T cells were stably transfected with plasmids encoding human VEGFR2 or its empty vector (HEK293T / VC), and the expression of VEGFR2 was detected using a clinically used VEGFR2 antibody, Ramucirumab. The flow cytometer results showed that the newly developed monoclonal antibody of the present invention and Ramucirumab had comparable abilities to bind to VEGFR2. The binding specificity of R2C7-1 and R2C9-11 antibodies to HEK293T / VC transfectants was also tested, and the results showed only trace staining. This result was further confirmed using a commercially available antibody against VEGFR2, Abcam9530 (data not shown).

[0052] R2C7-1 and R2C9-11 monoclonal antibodies also have affinity for binding to human lymphatic endothelial cells (HLEC) and HEK293T cells expressing VEGFR3. Flow cytometric analysis also showed that the newly developed monoclonal antibodies have unique affinity for HLECs (e.g. Figure 1 B). As previous literature has revealed that HLEC cells express a certain amount of VEGFR2 (see Dellinger et al., 2013, PLoS ONE 8(9): e74686.), HEK293T cells expressing VEGFR3 (HEK293T / VEGFR3) were designed to confirm the binding specificity of R2C7-1, R2C9-11 to VEGFR3, and the commercially available VEGFR3 antibody R&D54703 was used to detect the expression of VEGFR3 on HEK293T / VEGFR3 (data not shown). The results of flow cytometric analysis clearly showed that the two antibodies were different from Ramucirumab, and both antibodies were able to bind to VEGFR3 (e.g. Figure 1 D), and compared with R2C7-1, monoclonal antibody R2C9-11 can bind to VEGFR3 better. The data showed that the newly developed monoclonal antibody has dual binding ability to bind to VEGFR2 and VEGFR3, which also indicates that it may have the dual function of inhibiting angiogenesis and lymphangiogenesis.

[0053] Inhibits receptor dimerization induced by ligand

[0054] To test whether pretreatment with R2C7-1 and R2C9-11 monoclonal antibodies can prevent heterodimerization between VEGFR2 and VEGFR3, the HEL92.1.7 cell line with high VEGFR3 expression and low VEGFR2 expression and the HEK293T cell line expressing both VEGFR2 and VEGFR3 (HEK293T / VEGF-R2 / -R3) were used as experimental models. Whether using co-immunoprecipitation (IP) to precipitate VEGFR2 in HEL92.1.7 cells and dot analysis of VEGFR3 or precipitating VEGFR3 in HEK293T / VEGF-R2 / -R3 transfectant cells and analyzing VEGFR2, the results clearly showed that R2C7-1 and R2C9-11 monoclonal antibodies had better ability to inhibit receptor heterodimerization than Ramuciruman, especially R2C9-11 (such as Figure 2 A).

[0055] To further test whether the newly developed monoclonal antibodies have the ability to inhibit the homo- and / or hetero-dimerization of VEGF-A and VEGF-C, proximity ligation assay (PLA) was performed using HLEC cell lines. Cells were cultured in serum-free medium and pretreated with R2C7-1, R2C9-11, Ramucirumab or isotype control antibody (IgG2a), followed by VEGF-A 165 The cells were stimulated with VEGF-C or VEGF-C, and the distance between the receptors was used to determine whether homogeneous and / or heterogeneous dimerization was formed between VEGFR2 and VEGFR3. If the distance between the receptors was less than 40 nm, it was determined to be dimerization. Compared with unstimulated cells or the control group pretreated with IgG2a, the results showed that R2C7-1 and R2C9-11 monoclonal antibodies had a comparable inhibitory effect on VEGF-A as Ramucirumab. 165 The ability of the receptor to dimerize with VEGF-C (e.g. Figure 2 B). In summary, although the newly developed antibody has the ability to block receptor dimerization caused by VEGF-A and VEGF-C comparable to Ramucirumab, the newly developed antibody has a better effect of inhibiting heterodimerization than Ramucirumab.

[0056] Attenuation of downstream signaling of VEGFR2 and VEGFR3

[0057] After the receptor dimerizes due to the ligand, the receptor autophosphorylation and activation of downstream signal transduction pathways will inevitably occur due to the biological activity of the ligand. In order to test whether blocking receptor dimerization is sufficient to attenuate the activation of its downstream signal transduction pathways, HUVEC cells in a starved state were pretreated with monoclonal antibodies such as R2C7-1, R2C9-11 or their isotype control group (IgG2a), and cells pretreated with Ramucirumab were used as a control group. Then the cells were treated with VEGF-A165, serum stimulation or no treatment.

[0058] Western blot analysis of VEGFR2 autophosphorylation and its downstream signaling molecules (such as FAK p38MAPK) showed that both the newly developed monoclonal antibody and Ramucirumab could inhibit receptor dimerization and thus effectively inhibit VEGFR2 activation, especially tyrosine phosphorylation on its Y1054 residue, although the inhibitory effect of R2C7-1 was slightly weaker than that of Ramucirumab (data not shown).

[0059] Unlike the p38MARK dephosphorylation induced by Ramucirumab, the R2C7-1 monoclonal antibody did not have any effect on the activation of p38MARK, but effectively inactivated the activation of FAK. In addition, compared with Ramucirumab, R2C9-11 also has the effect of inhibiting the activity of p38MAPK (data not shown). In HLEC cells, the two newly developed antibodies have similar effects on the signal transduction induced by VEGF-A, and both can inhibit the autophosphorylation of VEGFR2 and VEGFR3 (data not shown), but on the contrary, only R2C9-11 can effectively inhibit the signal transduction pathway activated by VEGF-C, thereby inhibiting the activity of VEGFR3 (data not shown).

[0060] In summary, although R2C7-1 and R2C9-11 have different mechanisms for blocking the signal transduction pathway of VEGFR2, both have dual blocking properties and can block the receptor-mediated signal transduction activation of VEGFR2 and VEGFR3.

[0061] Blocking tube formation between 2D and 3D space

[0062] In order to test whether the newly developed antibodies' function of attenuating VEGF-A and VEGF-C-induced signal transduction can regulate the biological behavior of HUVEC and HLEC cells, a 2D space tube formation test was conducted. HUVEC and HLEC cells were first seeded on a well plate coated with matrix gel and lacking VEGFs and any nutritional supplements. After pretreatment with Ramucirumab, R2C7-1, R2C9-11 or isotype control group antibody (IgG2a), VEGF-A or VEGF-C was stimulated for 10 hours, and then images were captured. The total number of tube meshes and master segments was quantified using the angiogenesis analyzer of Image J. The results showed that compared with Ramucirumab's ability to inhibit angiogenesis induced by VEGF-A or VEGF-C, R2C9-11 had a better or equivalent inhibitory effect (e.g., Figure 3 ), however, the inhibitory effect of R2C7-1 monoclonal antibody was weaker in comparison.

[0063] To further test its effect of inhibiting the formation of sprouting fibrins in 3D space, HUVEC and HLEC cells were seeded on ultra-low plates containing CFSE fluorescent dye to form cell spheroids, and then transferred to wells coated with matrix gel and cultured for 7 days with medium containing R2C7-1, R2C9-11, Ramucirumab or isotype control group antibody (IgG2a). The sprouting area and fluorescence intensity were analyzed using NIS-AR software. The results showed that compared with the control group cells, all antibodies showed significant ability to inhibit the generation of sprouting fibers (P<0.001, as shown in Figure 2). Figure 4 A, 4B), and it is worth noting that the newly developed antibodies have better inhibitory effects than Ramucirumab. In summary, R2C7-1 and R2C9-11 monoclonal antibodies have different abilities to inhibit angiogenesis and lymphangiogenesis, and the differences depend on the experimental models used.

[0064] In vivo lymphangiogenesis induced by coat cells

[0065] Some literature has demonstrated that pericytes play an important role in angiogenesis and lymphangiogenesis (Ozerdem U, 2006, Ophthalmic Res. 2006; 38(5): 251-4). Therefore, in order to test whether WI38 fibroblasts as pericytes can promote lymphangiogenesis in vivo, HLEC cells were used as an experimental model and a Matrigel plug test was performed. HLEC / WI38 cells were mixed and implanted into ice-cold Matrigel, and then the Matrigel was subcutaneously inoculated into the ventral side of NOD-SCID mice. After two or four weeks, the polymerized Matrigel was removed, fixed, and embedded in paraffin. Subsequent immunohistochemical staining analysis was performed, using specific antibodies against human α-small muscle actin (SMA) and CD31 for double staining, and 3,3'-diaminobenzidine (DAB) and 3-amino-9-ethylcarbazole (AEC) were used to analyze human WI38 and HLEC cells in the matrix gel in the tissue. The results showed that two weeks after inoculation, WI38 cells marked by human SMA-specific antibodies could be seen infiltrating the newly formed blood vessels in the mouse tissue, earlier than the newly formed human lymphatic vessels marked by human CD31-specific antibodies; four weeks after inoculation, HLEC cells could be seen moving from the lower right to the upper left to form larger lymphatic vessels (data not shown). The above data can confirm that the outer layer cells do play an important role in lymphangiogenesis.

[0066] Reduce angiogenesis and lymphangiogenesis in vivo

[0067] Using the same experimental model as above, HUVEC or HLEC cells were mixed with WI38 and then implanted into Matrigel, which was then subcutaneously inoculated into NOD-SCID mice. The mice were then treated with Ramucirumab, R2C7-1, R2C9-11, or control group antibodies twice a week for a total of four weeks. The NIS-AR software was used to quantify the tubes partially or completely stained with AEC. The results showed that compared with the control group, the number of new blood vessels in mice treated with R2C7-1 or R2C9-11 was significantly reduced, and the effect was better than Ramucirumab, especially in the lymphatic newborn part (such as Figure 5 ) for better results.

[0068] In addition, the ratio of blood vessel size was further measured. The results showed that the ratio of blood vessels with a diameter greater than 50 μm in mice treated with R2C7-1, R2C9-11 or Ramucirumab was significantly decreased, while on the contrary, the ratio of blood vessels with a diameter less than 50 μm was significantly increased (e.g. Figure 6The above phenomenon also occurred in the lymphangiogenesis experimental model using HLEC cells, and the results also showed that compared with Ramucirumab, treatment with R2C7-1 and R2C9-11 could more effectively inhibit the formation of lymphangiogenesis (data not shown). Therefore, the above results show that compared with Ramucirumab, the newly developed antibody that can dually target VEGFR2 and VEGFR3 can provide better inhibition of angiogenesis and lymphangiogenesis.

[0069] Antibody-dependent tumor cell cytotoxicity in vivo and in vitro

[0070] Since the newly developed antibody can specifically target VEGFR3, it was further tested whether it has cytotoxicity to cells expressing VEGFR3. In this example, the HEL92.1.7 cell line was used. First, the expression of VEGFR2 and VEGFR3 was tested. Flow cytometry was used to confirm that it had high expression (~95%) of VEGFR3 and low expression (~5%) of VEGFR2 (such as Figure 7 A), and then peripheral blood mononuclear cells (PBMCs) were isolated from NOD-SCID mice for antibody-dependent cellular cytotoxicity (ADCC) assay. The results showed that all tested antibodies (including Ramucirumab) had the ability to kill HEL92.1.7 tumor cells in the presence of PBNCs and 2% infant serum, even when the antibody concentration was as low as 0.125μg / ml (e.g. Figure 7 B).

[0071] Next, the tumor inhibition ability of the antibody will be further tested through xenograft tumors in NOD-SCID mice. Cells with high (~95%) or low (~5%) expression of VEGFR3 were sorted and amplified, and inoculated into the left or right side of the mouse, respectively. Seven days after tumor inoculation, the mice were given R2C7-1, R2C9-11, Ramucirumab or IgG control antibodies twice a week for a total of 25 days. The results showed that the newly developed antibody had a therapeutic effect comparable to Ramucirumab for tumors with high or low expression of VEGFR3 (e.g. Figure 8 ). In summary, R2C7-1 and R2C9-11 not only have the dual function of inhibiting angiogenesis and lymphangiogenesis, but also can trigger the toxic effect of ADCC, thereby inhibiting the growth of tumors expressing VEGFR3, and have a therapeutic effect comparable to Ramucirumab within a 25-day treatment course.

[0072] Combination therapy of newly developed antibodies and Ramucirumab

[0073] To further test whether the combination of the newly developed antibody and Ramucirumab can provide better tumor suppression ability, mice bearing HEL92.1.7 tumor cells were used as experimental models (10 mice in each group) and were given R2C7-1, R2C9-11 or Ramucirumab alone or in combination. Seven days after the mice were inoculated, the antibodies were treated twice a week for a total of 35 days (total dose of 10 mg / kg). The results showed that compared with the treatment groups given R2C7-1 or R2C9-11 alone, the combination of R2C7-1 or R2C9-11 and Ramucirumab did not have a better tumor suppression therapeutic effect. On the contrary, R2C9-11 alone was the group that showed the best therapeutic effect among all antibody treatment groups (such as Fig. 9 Thus, the above data show that targeting tumor cells expressing VEGFR3 (such as HEL92.1.7) can not only reduce their cell survival, but also produce cytotoxicity due to antibody targeting in the presence of activated complement in infant serum.

[0074] Confirm epitopes on newly developed antibodies

[0075] To confirm the epitopes recognized by R2C7-1 and R2C9-11, a cell-based competitive ELISA (enzyme-linked immunosorbent assay) test was performed. HEK293T / VEGFR2 transfected cells were attached to a 96-well plate and fixed (5x10 4 Cells / well). Using standard ELISA procedures, the optimal concentrations of R2C7-1 and R2C9-11 antibodies binding to cells and the highest concentrations in the logarithmic phase were determined (data not shown). Next, a specific dose of a single immunoglobulin-like domain of the VEGFR2 antigen (R2-IgDs) was used to absorb the optimal concentration of antibodies to compete for their binding epitopes. The results showed that the main epitopes recognized by R2C7-1 and R2C9-11 were between IgD6 and IgD7, but there were slight differences between the two antibodies, and R2C7-1 had a stronger binding ability to IgD6 than R2C9-11 (e.g. Fig.10 ). In order to further determine the epitope of the newly developed antibody, an alanine scanning mutagenesis test was performed on it, which showed that any amino acid change between IgD6 and IgD7 of VEGFR2 would affect the binding ability of the two antibodies to it (data not shown). The above results indicate that the epitope recognized by the newly developed antibody of the present invention should be a structural epitope.

[0076] The same method as above was used to determine the epitope of antibody binding on VEGFR3, and HEK293T / VEGFR3 transfected cells were used as binding targets to determine the optimal concentration of antibody binding to VEGFR3 (data not shown). Next, a specific dose of a single immunoglobulin-like domain of the VEGFR3 antigen (R3-IgDs) was used to absorb the optimal concentration of antibody to compete for its binding epitope. The results showed that the main epitope recognized by R2C7-1 and R2C9-11 was located on IgD6 of VEGFR3, rather than IgD7 (such as Fig.11 A). To further confirm this result, Western blotting was performed on different recombinant IgD proteins. This was because previous literature has shown that IgD5 is removed by proteolytic reaction during the biosynthesis of VEGFR3 receptor (see Pajusola K et al., 1994, Oncogene. 9(12): 3545-55). In addition, in this example, it was not shown to be competitive in cell-based ELISA (e.g. Fig.11 A), so only E. coli system was used to synthesize IgD1-7, IgD3-4, IgD6-7 and other fragments. After non-reducing colloid electrophoresis, R2C7-1 and R2C9-11 antibodies were used to immunodetect the purified protein, which showed that the antibody had a high binding ability to IgD6-7, but not to IgD3-4 (e.g. Fig.11 B). In summary, these data all show that the epitopes bound by R2C7-1 and R2C9-11 on VEGFR2 and VEGFR3 are both located on IgD6-7, and the recognition site on the VEGFR3 protein is specifically located on IgD6.

[0077] Complementarity-determining regions (CDRs) and binding affinity

[0078] To determine the complementary determining regions of the antibodies, the Kabat and Chothia systems were used to establish the variable regions of the R2C7-1 and R2C9-11 antibodies. First, in order to determine that the fusion tumors secreting the two antibodies were single cells, the cells were screened by two consecutive dilutions, and the gene fragments with the antibody sequences were replicated using 5'-RACE or specific 5'- / 3'-IgG degenerative primers, see Table 1. The complementary determining region series replicated from the newly developed antibodies are shown in Table 2. The amino acid sequences of the heavy chain CDR1 (CDR-H1) and CDR2 (CDR-H2) defined by the Kabat and Chothia systems of R2C7-1 and R2C9-11 were very different, but there was no difference in their heavy chain CDR3 (CDR-H3). As for the CDRs of the light chain, the results identified by the two systems showed that there was no difference between the two antibodies. In summary, although R2C7-1 and R2C9-11 have binding potential to the IgD6-7 domains of VEGFR2 and VEGFR3, it is possible that the CDR amino acid sequences between R2C7-1 and R2C9-11 are different, which leads to different binding epitopes of the two antibodies on VEGFR2 and VEGFR3.

[0079] Table 1. Sequences of VEGFR2 monoclonal antibodies

[0080]

[0081]

[0082] Table 2. Complementarity determining regions of VEGFR2 monoclonal antibodies

[0083]

[0084] Note: The complementarity determining regions of monoclonal antibodies are defined by the Kabat or Chothia numbering system.

[0085] To detect the binding affinity of R2C7-1 and R2C9-11, recombinant IgD4-7 and IgD6-7 of VEGFR2 (KDR) and VEGFR3 (Flt-4) were used as target antigens, and the binding affinity was measured using the Biacore system. The results are shown in Table 3, showing that the affinity of R2C9-11 for IgD4-7 and IgD6-7 antigens of VEGFR2 and VEGFR3 was higher than that of R2C7-1, and that any antibody showed stronger binding to VEGFR2 than to VEGFR3. In addition, the binding of the two newly developed antibodies to IgD4-72 of VEGFR2 or VEGFR3 was slightly higher than that to IgD6-7. These data also show that the epitopes recognized by R2C7-1 and R2C9-11 depend on the 3D structure of the extracellular domains of VEGFR2 and VEGFR3.

[0086] Table 3. Binding affinity of R2C7-1 and R2C9-11 detected by Biacore

[0087]

[0088]

[0089] Materials and Methods

[0090] (1) Cell culture

[0091] NHK293T cells were cultured in DMEM containing 10% FBS and 1X antibiotic-antimycotic (GIBCO; Grand Island, NY) at 37°C in a 5% CO2 incubator. Human umbilical vein endothelial cells (HUVECs) were cultured in endothelial basal medium-2 (EGM-2) supplemented with various growth factors, cytokines, and other supplements from the SingleQuot reagent set (Lonza; Basel, Switzerland) at 37°C in a 5% CO2 incubator. The primary cells used in the experiment were approximately the 3rd to 6th passages. Human lymphatic endothelial cells (LECs) were purchased from Promocell (Heidelberg Germany) and cultured in endothelial cell culture medium MV (Promocell) according to the manufacturer's instructions.

[0092] (2) Generation of fusion tumors

[0093] BALB / C mice were immunized intraperitoneally three times over two weeks with human recombinant immunoglobin (Ig) domains 4-7 of vascular endothelial growth factor receptor 2 (VEGFR2). The gene encoding the extracellular domains 4-7 of VEGFR2 was cloned into the pGEX-KG vector using gene-specific primers and human VEGFR2 cDNA as templates. The resulting plasmid was confirmed by direct sequencing and named pGEX-VEGFR2-ED Ig D4-7. The encoded protein was expressed in an E. coli expression system and purified using glutathione-conjugated Sepharose beads (Sigma-Aldrich; St. Louis, MO). The relevant methods are described in "Gene Construction and Expression" below. The serum of mice was collected and tested for the presence of anti-VEGFR2 antibodies using an indirect ELISA. After high antibody titers (>1:3000 dilution) were detected, mice were given a final IP boost of 25 μg of recombinant antigen without Freund's adjuvant. Five days after the final boost, mice were sacrificed and spleen cells were collected and fused with myeloma cells using a modified fusion tumor technique (Apiratmateekul, N., P. Phunpae, and W. Kasinrerk, Cytotechnology, 2009. 60(1-3): p. 53.). Briefly, spleen cells (7x10 7 cells) and 2x10 7 Sp2 / 0-Ag14 cells (ATCC CRL-1581TM) were fused using standard fusion tumor technology and screened with HAT medium (Sigma-Aldrich). The culture supernatants obtained from the wells containing fusion tumors were analyzed using a standard indirect ELISA. 450nm ), fusion tumors with an optical density of ≥0.60 were determined as positive, and single-cell replication was performed using the limiting dilution technique. The isotype of secreted mouse monoclonal antibodies was determined using the mouse monoclonal antibody isotype reagent set (Thermo Scientific Pierce, Rockford, IL).

[0094] (3) Antibody purification

[0095] Fusion tumors producing anti-VEGFR2 monoclonal antibodies were cultured in the absence of serum using Fusion tumor serum-free medium (Gibco), and monoclonal antibodies were purified from the culture supernatant using affinity chromatography using TOYOPEARL AF-rProtein A (Griesheim, Germany). After washing with ice-cold PBS (10x bed volume), the antibodies purified by Protein A magnetic beads were eluted with elution buffer (50 mM glycine-HCl, pH 3.0 for R2C7-1 and 50 mM glycine-HCl / 150 mM NaCl, pH 3.0 for R2C9-11), and each 1 mL fraction of the elution was collected in 100 μL of neutralization buffer (1 M Tris-HCl, pH 8.0 / 1.5 M NaCl / 1 mM The monoclonal antibody was dialyzed against PBS overnight at 4°C and stored at -80°C for subsequent use.

[0096] (4) Tube formation test

[0097] Culture plates were coated with ice-cold Matrigel (80 μL / well; BD Biosciences, San Jose, CA) and incubated at 37°C for 30 min to form a gel. LECs and HUVECs were starved for 8 h in EGM-2 in the absence of VEGFs and other supplements, then trypsinized and resuspended in medium containing Ramucirumab (5 μg / mL; Eli Lilly, Indianapolis, IN), anti-VEGFR2 monoclonal antibodies (20 μg / mL; R2C7-1 or R2C9-11), and 2 μg / mL of VEGF-A165 (Cys156Ser) or VEGF-C (R&D; McKinley Place, NE). LECs or HUVECs were then seeded onto the pre-coated plates and incubated at 37°C for 4 or 10 h, respectively. The whole-body images of the well plates were captured using the NIKON Digital Slight DS-U3 system (Tokyo, Japan), and the total number of branch nodes, tube networks, and tube lengths were quantified using the Angiogenesis Analyzer in Image J. The data were obtained by performing three replicates and are presented as mean ± SD.

[0098] (5) Flow cytometric analysis

[0099] The cells were washed with phosphate-buffered saline (PBS) and dissolved in EDTA based on PBS. The cells were collected by centrifugation and incubated in PBS containing 1% bovine serum albumin for 1 h at 4°C to block nonspecific binding. After subsequent PBS washing, HUVEC or HEK293T cells expressing VEGFR2 (1×10 5 To detect VEGFR3 expression, LECs or HEK293T cells expressing VEGFR3 were first detected using VEGFR3 antibody (Santa Cruz, Dallas, TX) or control rabbit IgG antibody (Abcam, Burlingame, CA) as immunoprobes. After extensive washing in PBS containing 1% BSA, cells were stained with the corresponding secondary antibodies, goat anti-mouse IgG with PE (Biolegend), donkey anti-rabbit IgG with FITC (Abcam), or mouse anti-human IgG with PE (Biolegend) at 4 μg / mL for 1 hour at 4°C. Cells were then washed again and resuspended in PBS containing 1% paraformaldehyde and 1% BSA and analyzed using a BD FACSCalibur. TM Flow cytometry (Becton Dickinson, Franklin Lakes, NJ) was used to analyze the expression of VEGFR2 and VEGFR3 on the cell surface.

[0100] (6) In situ proximity ligation assay (PLA)

[0101] The Duolink in-situ PLA reagent set (Sigma-Aldrich, St. Louis, MO) was used according to the manufacturer's instructions to detect the effect of anti-VEGFR2 monoclonal antibodies (R2C7-1, R2C9-11) in blocking the homo- / heterodimerization of VEGFR2 and VEGFR3. Briefly, LECs were seeded in 8-well cell culture slides and cultured in serum-free medium containing R2C7-1, R2C9-11, or Ramucirumab (Eli Lilly) for 16 h. After stimulation with VEGF-C (500 ng / mL for 15 min), VEGF-C (Cys156Ser) (2 μg / mL for 10 min), or VEGF-A165 (50 ng / mL for 5 min), the cells were rinsed with PBS and fixed with 4% paraformaldehyde for 15 min. The cells were then treated with blocking buffer (Sigma-Aldrich) at room temperature for 30 min. The cells were then stained with 2 μg / mL of commercially available anti-VEGFR2 or VEGFR3 (Santa Cruz, Dallas, TX) TX) antibody staining was used as a control group, and the corresponding species-specific secondary antibodies that can be linked to specific oligonucleotides (PLA probes) were added. The PLA probe ligation reaction was completed by adding a solution containing ligase (Sigma-Aldrich) (final concentration of 1 unit / μL) at 37°C for 30 minutes, and the ligated PLA probe was reacted with a solution containing polymerase (Sigma-Aldrich) (concentration of 10 units / μL) at 37°C for 100 minutes to amplify the signal. After washing with buffer B (Sigma-Aldrich), the cell nuclei on the slides were stained with DAPI, and then the slides were mounted with Duolink in-situ mounting medium (Sigma-Aldrich). In addition, isotype IgG was used as a control group. The fluorescent signals (or spots) of the above staining were all used for movie imaging and analysis using MetaMorph Offline software.

[0102] (7) Co-immunoprecipitation analysis

[0103] To test whether anti-VEGFR2 antibodies have an inhibitory effect on VEGF-C-induced receptor dimerization, LEC cells were first seeded on 6-cm diameter culture dishes until the cells grew to 70-80% confluence, then the cells were washed and cultured in serum-free medium containing 20 μg / mL of antibodies (R2C7-1, R2C9-11, or isotype control antibodies) for 16 hours. Subsequently, the cells were divided into two groups, stimulated with VEGF-C (500 ng / mL) for 15 minutes, or not treated with VEGF-C, and then washed twice with ice-cold PBS and then used RIPA buffer (20 mM Tris-HCl (pH 7.5) / 150 mM NaCl / 1 mM Na2EDTA / 1 mM EGTA / 1% NP-40 / 1% sodium deoxycholate / 2.5 mM sodium pyrophosphate / 1 mM β-glycerophosphate / 1 mM Na3VO4 / 1 μg / mL For immunoprecipitation, lysates (1 mg / sample) were pretreated with Protein-A / G-agarose magnetic beads (Thermo Fisher; Waltham, MA) to minimize other nonspecific binding, and then incubated with anti-VEGFR3 antibody (1 μg / sample, Santa Crus) at 4°C overnight with continuous rotation. Immunoprecipitated proteins were separated by native polyacrylamide gel electrophoresis and immunoblotted with a commercially available VEGFR3 antibody (Santa Crus), followed by staining using an ECL Western blotting system (ThermoScientific) as described below.

[0104] (8) Native colloidal electrophoresis

[0105] The receptor dimerization state of VEGFR2 and VEGFR3 was measured by native gel electrophoresis (PAGE). First, cells were starved and cultured in serum-free medium containing 20 μg / mL R2C7-1 or R2C9-11 for 16 hours. Ramucirumab and isotype control antibodies were used as positive and negative controls, respectively. Then, cells were stimulated with VEGF-C (500 ng / ml) for 15 minutes and then collected with hypotonic lysis buffer (20 mM Tris-HCl, pH 7.4, 10 mM NaCl, 1 mM PMSF). Equal amounts of protein samples were mixed with 4x native sample buffer (400 mM Tris-HCl, pH 7.5, 40% glycerol, 0.02% bromophenol blue) and native gel electrophoresis was performed using pre-made PAGE gels (Bio-Rad). Anti-VEGFR2, anti-VEGFR3, or anti-p-VEGFR3 antibodies (Santa Cruz, Santa Cruz, Cruz, Cell Applications; San Diego, CA) to detect the dimerization and phosphorylation status of VEGFRs.

[0106] (9) Western blot analysis

[0107] Protein lysates were obtained by lysing cells using lysis buffer (20 mM Tris-HCl pH 8.0 / 2 mM EDTA / 1 mM Na3VO4 / 10% glycerol / 1% Triton X-100 / protease) with the addition of a phosphatase inhibitor cocktail (Sigma-Aldrich) or RIPA buffer.HUVEC and LEC cells were seeded one day before treatment. Anti-VEGFR2 antibodies, such as R2C7-1 or R2C9-11, were added to HUVEC cells in culture medium (5, 10, 20 μg / mL) and treated at 37°C for 10 minutes. HUVEC were then stimulated with 20 ng / mL VEGF-A165 (R&D). LEC cells were pre-cultured with R2C7-1 or R2C9-11 antibodies (20 μg / mL) and then stimulated with VEGF-C (500 ng / mL for 15 minutes), VEGF-C (Cys156Ser) (2 μg / mL for 10 minutes) or VEGF-A165 (50 ng / mL for 5 minutes) (R&D). Cells were then harvested with RIPA buffer and incubated with Ramucirumab (5 μg / mL; Eli Lilly) and the like. Lilly) and isotype control IgG (mouse IgG (Biolegend) for R2C7-1 and R2C9-11; rabbit IgG (Abcam) for rabbit IgG for VEGFR3) were used as positive and negative controls. The protein concentrations obtained by extraction were measured by Bradford protein assay (Bio-Rad). The same amount of total protein (50 μg / sample) was separated by electrophoresis on 12% sodium dodecyl sulfate polyacrylamide gel (Bio-Rad). The proteins were then transferred to nitrocellulose membranes (HybondTM-P; Amersham Biosciences, Piscataway, NJ). After blocking with blocking buffer (3% BSA / 0.1% Tween-20 in TBS) at room temperature for two hours, the membranes were incubated with anti-VEGFR2 (Santa Cruz), anti-VEGFR3 (Santa Cruz), and anti-VEGFR4 (Santa Cruz). Cruz), anti-p-VEGFR3 (Tyr1230 / 1231) (Cellapplications), anti-p-FAK, anti-p-p38ERK (Cell Signaling; Danvers, MA), anti-β-Actin (MilliporeSigma; Burlington, MA), or anti-tubulin primary antibodies were incubated overnight at 4°C, followed by incubation with the corresponding secondary antibodies conjugated with horseradish peroxidase (HRP), and the immunoreactive proteins were visualized using SuperSignal West Pico chemiluminescence (Thermo Scientific), and the signals were detected using X-ray film (FUJU; Tokyo, Japan).

[0108] (10) Cell-based competitive ELISA

[0109] The antibody epitopes of anti-VEGFR2 antibodies R2C7-1 and R2C9-11 were determined using a cell-based competitive ELISA. HEK293T cells expressing VEGFR2 or VEGFR3 were first seeded in a 96-well plate at a concentration of 50,000 cells / 100 μL per well and cultured overnight at 37°C. After sufficient washing, the cells were fixed with a PBS solution containing 1% glutaraldehyde and washed three times with a PBS solution containing 0.1% Tween-20 (PBST). The cells were then treated with a PBS solution containing 3% BSA at 37°C for 30 minutes to avoid nonspecific binding. On the other hand, R2C7-1 and R2C9-11 antibodies (8 μg / well plate) were treated with designated doses (0.2, 1.0, 5.0 μg / well plate) of single globin-like domains (IgD4, D5, D6, D7) of VEGFR2 or VEGFR3 recombinant protein were absorbed at 37°C for 30 minutes, and then the cells expressing VEGFR2 or VEGFR3 were co-incubated with the pre-absorbed R2C7-1 or R2C9-11 antibodies at 37°C for 1 hour and washed three times with a large amount of PBST. Finally, goat anti-mouse IgG with HRP was used as a probe to detect the bound antibody at 37°C for 1 hour, and ABTS was added for color development (37°C, treatment for 30 minutes), and the SpectraMax M5 microplate reader (Molecular Device; San Jose, CA) was used to read the cells at OD 405 Next measurement.

[0110] (11) Gene construction and expression

[0111] The extracellular globulin (Ig) domain of VEGFR2 was constructed into the pGEX-4T-1 plasmid (GE Healthcare; Chicago, IL) and the recombinant protein was expressed in a competent E. coli cell system. The genes of the extracellular globulin domain of VEGFR2 and its subdomains 6 and 7 (NM_002253.2) were generated by PCR using plasmid EX-I0114-Lv205 (GeneCopoeia; Rockville, MD) as a template and gene-specific primers, and then restricted digested with BamH1 and Xhol (NEB; Ipswich, MA) and cloned into the pGEX-4T-1 vector (GE Healthcare; Chicago, IL) and named VEGFR2-ED Ig D1-7 and D6-7, respectively. The gene construct was then transformed into JM109 cells (Promega; Madison, WI) by heat shock treatment at 42°C for 40 seconds and screened on LB agar with Ampicillin (50 μg / mL). The inserted gene in antibiotic-resistant cells was confirmed by standard colony PCR and gene sequencing. Positive cells were cultured in LB medium containing Ampicillin and treated with 1 mM IPTG (Sigma-Aldrich) at 37°C for 3 hours to induce cell expression of protein. The cells were then pelleted, broken up and suspended in ice-cold lysis buffer (10 mM Tris-HCl pH 8.0 / 0.15 M NaCl / 1 mM EDTA) and added with 100 μg / mL lysozyme, 10 mM PMSF, and 5 units of benzonase (Sigma-Aldrich). After sonication treatment, the soluble fragments were obtained by centrifugation at 10,000 x g for 30 minutes. The GST-tagged recombinant protein was purified with Sepharose magnetic beads with glutathione (Sigma-Aldrich). The protein was eluted with 10 mM reduced glutathione and dialyzed against PBS overnight. Finally, the purity of the recombinant protein was determined by SDS-PAGE.

[0112] To express the extracellular domain gene of VEGFR3 in eukaryotic cells, the gene to be inserted was cloned into the pCMV6-XL6-myc vector (OriGene; Rockville, MD) to express the protein. Briefly, the genes of the extracellular Ig domain and its secondary domain of VEGFR3 (NM_002020.4) were amplified by PCR using gene-specific primers using pCMV6-XL6-VEGFR3 (given by Dr. JL Su) as a template. After restriction digestion, the insert was cloned into the EcoR1 and Xbal sites of pCMV6-XL6 (OriGene; Rockville, MD), and then transformed into DH5α cells (ThermoScientific) to amplify the gene, and the resulting VEGFR3-ED Ig D1-7, D3-4, D6-7-myc plasmids were confirmed by direct sequencing.

[0113] To express and purify the recombinant protein encoded by the plasmid, HEK293 cells were transfected with Turofect transfection reagent (Thermo Scientific) according to the instructions in the product manual, and the encoded protein was purified using anti-Mycantibody-mobilized columns, dissolved in native PAGE gels using Native Page Novex Bis-Tris gel system (Invitrogen; Carlsbad, CA), and then immunoblotted on nitrocellulose membranes. In addition, to detect the cross-reaction of VEGFR2 antibodies, R2C7-1 or R2C9-11 antibodies were used as probes to detect the blots, and goat anti-mouse IgG-HRP (Santa Cruz) antibodies were used to detect the signals, and then SuperSignal West Picochemiluminescence (Thermo Scientific) was used to visualize the signals.

[0114] Other embodiments

[0115] All technical features disclosed in this specification can be combined in any combination, and each technical feature disclosed in this specification can be replaced by an alternative technical feature with the same, equivalent or similar purpose. Therefore, unless otherwise explicitly stated, each technical feature disclosed is merely an embodiment of a series of identical or similar technical features.

[0116] Based on the above description, a person with ordinary knowledge in the art can easily understand the basic features of the described embodiments, and can make various changes and modifications to the embodiments without departing from the spirit and scope thereof to make them suitable for various uses and conditions. Therefore, other embodiments should also fall within the scope of the claims of this case. Sequence Listing <110> National Institute of Health <120> Bifunctional antibodies targeting VEGFR2 and VEGFR3 <130> GCI20TW6129 <150> US 62 / 645,437 <151> 2018-03-20 <160> 20 <170> PatentIn version 3.5 <210> 1 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> R2C7-1 VH <400> 1 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr 20 25 30 Phe Ile Asn Trp Val Ile Gln Arg His Gly Lys Ser Leu Glu Trp Val 35 40 45 Gly Arg Ile Asn Pro Tyr Asn Gly Gly Ser Phe Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Ile Ala His 65 70 75 80 Met Glu Leu Arg Ser Leu Ala Ser Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Ser Gly Gly Asn Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 2 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> R2C7-1 VL <400> 2 Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Ile Pro Gly 1 5 10 15 Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His 85 90 95 Leu Glu Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 3 <211> 114 <212> PRT <213> Artificial Sequence <220> <223> R2C9-11 VH <400> 3 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Leu Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val 100 105 110 Ser Ser <210> 4 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> R2C9-11 VL <400> 4 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Asn Leu Leu Asn Ser 20 25 30 Gly Asn Gln Lys Tyr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Ile Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Ser 85 90 95 Asp His Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 100 105 110 Lys <210> 5 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> R2C7-1 VH CDR-1; Kabat <400> 5 Asp Tyr Phe Ile Asn 1 5 <210> 6 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> R2C7-1 VH CDR-2; Kabat <400> 6 Arg Ile Asn Pro Tyr Asn Gly Gly Ser Phe Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 7 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> R2C7-1 VH CDR-3 <400> 7 Ser Gly Gly Asn Gly Tyr Asp Tyr 1 5 <210> 8 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> R2C7-1 VH CDR-1; Chothia <400> 8 Gly Tyr Ser Phe Thr Asp Tyr 1 5 <210> 9 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> R2C7-1 VH CDR-2; Chothia <400> 9 Asn Pro Tyr Asn Gly Gly 1 5 <210> 10 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> R2C7-1 VL CDR-1 <400> 10 Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr 1 5 10 15 <210> 11 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> R2C7-1 VL CDR-2 <400> 11 Arg Met Ser Asn Leu Ala Ser 1 5 <210> 12 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> R2C7-1 VL CDR-3 <400> 12 Met Gln His Leu Glu Tyr Pro Tyr Thr 1 5 <210> 13 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> R2C9-11 VH CDR-1; Kabat <400> 13 Ser Tyr Trp Met His 1 5 <210> 14 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> R2C9-11 VH CDR-2; Kabat <400> 14 Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Ser <210> 15 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> R2C9-11 VH CDR-3 <400> 15 Leu Tyr Phe Asp Val 1 5 <210> 16 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> R2C9-11 VH CDR-1; Chothia <400> 16 Gly Tyr Thr Phe Thr Ser Tyr 1 5 <210> 17 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> R2C9-11 VH CDR-2; Chothia <400> 17 Asn Pro Ser Asn Gly Arg 1 5 <210> 18 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> R2C9-11 VL CDR-1 <400> 18 Lys Ser Ser Gln Asn Leu Leu Asn Ser Gly Asn Gln Lys Tyr Tyr Leu 1 5 10 15 Ala <210> 19 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> R2C9-11 VL CDR-2 <400> 19 Gly Ala Ser Ile Arg Glu Ser 1 5 <210> 20 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> R2C9-11 VL CDR-3 <400> 20 Gln Ser Asp His Ser Tyr Pro Tyr Thr 1 5

Claims

1. An antibody comprising: (a) a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 5, a VHCDR2 amino acid sequence of SEQ ID NO: 6, and a VHCDR3 amino acid sequence of SEQ ID NO: 7; and a light chain variable region (VL) comprising a light chain complementary determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 12; or (b) a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 8, a VHCDR2 amino acid sequence of SEQ ID NO: 9, and a VHCDR3 amino acid sequence of SEQ ID NO: 7; and a light chain variable region (VL) comprising a light chain complementary determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 12; or (c) a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 13, a VHCDR2 amino acid sequence of SEQ ID NO: 14, and a VHCDR3 amino acid sequence of SEQ ID NO: 15; and a light chain variable region (VL) comprising a light chain complementary determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 18, a VLCDR2 amino acid sequence of SEQ ID NO: 19, and a VLCDR3 amino acid sequence of SEQ ID NO: 20; or (d) a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 16, a VHCDR2 amino acid sequence of SEQ ID NO: 17, and a VHCDR3 amino acid sequence of SEQ ID NO: 15; and a light chain variable region (VL) comprising a light chain complementary determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 18, a VLCDR2 amino acid sequence of SEQ ID NO: 19, and a VLCDR3 amino acid sequence of SEQ ID NO: 20; The antibody can specifically bind to vascular endothelial growth factor receptor 2 (VEGFR2) and vascular endothelial growth factor receptor 3 (VEGFR3).

2. The antibody of claim 1, wherein the antibody is a humanized antibody.

3. The antibody of claim 2, wherein the antibody is an antibody comprising an Fc region, a Fab fragment, a Fab' fragment, a F(ab)'2 fragment, a single-chain antibody, a scFV multimer, a monovalent antibody, a multispecific antibody or a chimeric antibody.

4. The antibody of claim 1, wherein (a) the amino acid sequence of the heavy chain variable region is SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is SEQ ID NO: 2 or (b) the amino acid sequence of the heavy chain variable region is SEQ ID NO: 3, and the amino acid sequence of the light chain variable region is SEQ ID NO:

4.

5. A pharmaceutical composition comprising the antibody according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

6. An antibody conjugate comprising the antibody according to any one of claims 1 to 4 and a molecule.

7. Use of the antibody according to claim 1 for the manufacture of a pharmaceutical product having a therapeutic effect on VEGFR2 and / or VEGFR3-expressing leukemia, wherein: The treatment is by inhibiting angiogenesis and / or lymphangiogenesis in a subject's tumor.

8. The use of claim 7, further comprising administering another therapeutic agent to the subject.

9. A method for detecting VEGFR2 and / or VEGFR3 or fragments thereof in a biological sample for non-diagnostic purposes, comprising: contacting the biological sample with the antibody according to any one of claims 1 to 4; The specific binding between the antibody and VEGFR2 and / or VEGFR3 or fragments thereof is determined.